Brepocitinib

Phase 2Small molecule

PPriovant Therapeutics, Inc.

Brepocitinib is one of 89 small molecule programs targeting Anterior Uveitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anterior UveitisActive, not recruiting

SarcoidosisActive, not recruiting

DermatomyositisActive, not recruiting

Anterior UveitisPhase 2

Active, not recruiting

SarcoidosisPhase 2

Active, not recruiting

DermatomyositisPhase 2

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Sarcoidosis

#DrugCompanyPhaseTrials

Daliresp

AstraZeneca

Approved

1 2

Calciferol

Alnylam Pharmaceuticals

Approved

1 3

Esbriet

LLegacy Health System

Approved

1 4

Ofev

Boehringer Ingelheim

Approved

1 5

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—6

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—7

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Glucophage

Rayos

Decadron

AAspen Global Incorporated

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Sarcoidosis

NCT06978725

Q1 2028

Phase 3Active, not recruiting

Anterior Uveitis

NCT06431373

Clinical

Trials by Indication[1]

Dermatomyositis2 trials

A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis

Active, not recruiting·PPriovant Therapeutics, Inc.·Phase 3·NCT05437263·241 enrolled

A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis

Completed·PPriovant Therapeutics, Inc.·Phase 2·NCT06433999·5 enrolled

Anterior Uveitis2 trials

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

Completed·PPriovant Therapeutics, Inc.·Phase 2·NCT05523765·26 enrolled

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Active, not recruiting·PPriovant Therapeutics, Inc.·Phase 3·NCT06431373·371 enrolled

Sarcoidosis1 trial

A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

Recruiting·PPriovant Therapeutics, Inc.·Phase 2·NCT06978725·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Brepocitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Brepocitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Brepocitinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Priovant Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPriovant Therapeutics, Inc.

Brepocitinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Trials by Indication[1]

Dermatomyositis2 trials

Anterior Uveitis2 trials

Sarcoidosis1 trial

References

Drug Info

Quick Facts

Related News